| Abstrakt: |
A patent application has been filed for a process to make a recombinant antidote to Factor Xa inhibitor, an anticoagulant used to prevent blood clots. The invention aims to address the bleeding risk associated with anticoagulant therapy by providing a specific and effective antidote. The application describes methods and cells for increased production of functional antidote proteins, including the use of Furin to improve processing. The patent application provides detailed information on the isolated cells, polynucleotide constructs, and methods involved in the production of the antidote. [Extracted from the article] |
